CY1108701T1 - Ρυθμιστες του γλυκοπρωτεϊνικου προσδεματος 1 της ρ-σελεκτινης. - Google Patents

Ρυθμιστες του γλυκοπρωτεϊνικου προσδεματος 1 της ρ-σελεκτινης.

Info

Publication number
CY1108701T1
CY1108701T1 CY20091100020T CY091100020T CY1108701T1 CY 1108701 T1 CY1108701 T1 CY 1108701T1 CY 20091100020 T CY20091100020 T CY 20091100020T CY 091100020 T CY091100020 T CY 091100020T CY 1108701 T1 CY1108701 T1 CY 1108701T1
Authority
CY
Cyprus
Prior art keywords
cell
selectin glycoprotein
regulators
induce
cells
Prior art date
Application number
CY20091100020T
Other languages
Greek (el)
English (en)
Inventor
Rong-Hwa Lin
Chung-Hsiun Wu
Pei-Ling Hsu
Original Assignee
Abgenomics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Corporation filed Critical Abgenomics Corporation
Publication of CY1108701T1 publication Critical patent/CY1108701T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
CY20091100020T 2001-08-03 2009-01-13 Ρυθμιστες του γλυκοπρωτεϊνικου προσδεματος 1 της ρ-σελεκτινης. CY1108701T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31019601P 2001-08-03 2001-08-03
US10/051,497 US7744888B2 (en) 2001-08-03 2002-01-18 Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
EP02733839A EP1411982B1 (en) 2001-08-03 2002-03-13 Modulators of p-selectin glycoprotein ligand 1

Publications (1)

Publication Number Publication Date
CY1108701T1 true CY1108701T1 (el) 2014-04-09

Family

ID=26729479

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100020T CY1108701T1 (el) 2001-08-03 2009-01-13 Ρυθμιστες του γλυκοπρωτεϊνικου προσδεματος 1 της ρ-σελεκτινης.
CY20121100115T CY1112966T1 (el) 2001-08-03 2012-02-01 Αντισωμα δεσμευον το γλυκοπρωτεϊνικο προσδεμα 1 της p-σελεκτινης (ρsgl-1) για χρηση στην αγωγη αλλεργικης νοσου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100115T CY1112966T1 (el) 2001-08-03 2012-02-01 Αντισωμα δεσμευον το γλυκοπρωτεϊνικο προσδεμα 1 της p-σελεκτινης (ρsgl-1) για χρηση στην αγωγη αλλεργικης νοσου

Country Status (19)

Country Link
US (3) US7744888B2 (enExample)
EP (2) EP1411982B1 (enExample)
JP (3) JP4815101B2 (enExample)
KR (1) KR100850731B1 (enExample)
CN (2) CN1304051C (enExample)
AT (2) ATE531734T1 (enExample)
AU (1) AU2002305041B2 (enExample)
CA (1) CA2428822C (enExample)
CY (2) CY1108701T1 (enExample)
DE (1) DE60229394D1 (enExample)
DK (2) DK1985634T3 (enExample)
ES (2) ES2316569T3 (enExample)
IL (4) IL160168A0 (enExample)
MX (1) MXPA04001047A (enExample)
NO (2) NO333456B1 (enExample)
NZ (1) NZ531199A (enExample)
PT (2) PT1411982E (enExample)
TW (1) TWI327070B (enExample)
WO (1) WO2003013603A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
EP1663290A4 (en) * 2003-09-15 2009-07-01 Abgenomics Corp MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGANDS 1
US7459523B2 (en) * 2003-11-12 2008-12-02 Wisconsin Alumni Research Foundation Equine P-selectin glycoprotein ligand-1 and uses thereof
AU2012201999C1 (en) * 2004-05-10 2016-05-12 Abgenomics Cooperatief U.A. Antibodies
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
BRPI0510561A (pt) * 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
WO2007033959A2 (en) * 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
AU2009246166B2 (en) * 2008-05-15 2014-09-18 Tetherex Pharmaceuticals Corporation Anti-PSGL-1 antibodies and methods of identification and use
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
EP4079324A1 (en) * 2014-07-08 2022-10-26 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof
WO2017120534A1 (en) 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
US20170241415A1 (en) * 2016-02-19 2017-08-24 Muzan, Inc. Sanitary check valve
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
CN114158275A (zh) * 2019-05-03 2022-03-08 香港大学 腹膜转移细胞的检测和分离方法
KR20220042055A (ko) * 2019-06-04 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도
WO2025168211A1 (en) * 2023-02-10 2025-08-14 Novo Nordisk A/S P-selectin peptide ligands

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
DE69415154T2 (de) * 1993-01-25 1999-07-29 Dana-Farber Cancer Institute, Inc., Boston, Mass. Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
DE69630307T2 (de) 1995-08-03 2004-07-15 The Board Of Regents Of The University Of Oklahoma, Norman O-glycaninhibitoren von selectinvermittelten entzüngen
JPH09227410A (ja) 1996-02-21 1997-09-02 Sumitomo Pharmaceut Co Ltd 臓器移植拒絶反応の抑制剤
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
CN1342085A (zh) 1998-10-30 2002-03-27 遗传研究所有限公司 通过p－选择素配体(psgl)拮抗剂抑制细胞素t细胞的分化
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
PL366223A1 (en) 2000-12-29 2005-01-24 Bio-Technology General Corp. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
BRPI0510561A (pt) 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
CN101045161A (zh) 2007-10-03
EP1411982A4 (en) 2004-10-06
CN101045161B (zh) 2010-06-16
EP1411982A1 (en) 2004-04-28
HK1124624A1 (en) 2009-07-17
NO333456B1 (no) 2013-06-10
ES2316569T3 (es) 2009-04-16
US8298540B2 (en) 2012-10-30
DK1411982T3 (da) 2009-02-16
EP1411982B1 (en) 2008-10-15
AU2002305041B2 (en) 2005-11-10
JP2008260759A (ja) 2008-10-30
JP2012092144A (ja) 2012-05-17
MXPA04001047A (es) 2005-02-17
CN1473052A (zh) 2004-02-04
ATE531734T1 (de) 2011-11-15
IL204030A (en) 2014-11-30
US8557579B2 (en) 2013-10-15
NO20040460L (no) 2004-02-24
JP4815101B2 (ja) 2011-11-16
JP2004521958A (ja) 2004-07-22
IL160168A0 (en) 2004-07-25
WO2003013603A8 (en) 2004-06-10
IL210557A0 (en) 2011-03-31
WO2003013603A1 (en) 2003-02-20
US20030049252A1 (en) 2003-03-13
CN1304051C (zh) 2007-03-14
CY1112966T1 (el) 2016-04-13
PT1985634E (pt) 2012-02-07
EP1985634B1 (en) 2011-11-02
KR20040054670A (ko) 2004-06-25
US7744888B2 (en) 2010-06-29
IL204030A0 (en) 2011-08-01
NZ531199A (en) 2004-11-26
DE60229394D1 (en) 2008-11-27
IL160168A (en) 2011-02-28
US20130011861A1 (en) 2013-01-10
DK1985634T3 (da) 2012-02-20
ES2376948T3 (es) 2012-03-21
EP1985634A1 (en) 2008-10-29
KR100850731B1 (ko) 2008-08-06
CA2428822A1 (en) 2003-02-20
ATE411045T1 (de) 2008-10-15
TWI327070B (en) 2010-07-11
NO334850B1 (no) 2014-06-16
CA2428822C (en) 2014-10-28
HK1065489A1 (en) 2005-02-25
NO20130069L (no) 2004-02-24
US20090304709A1 (en) 2009-12-10
PT1411982E (pt) 2008-12-24

Similar Documents

Publication Publication Date Title
IL204030A0 (en) Modulators of p-selectin glycoprotein ligand 1
WO2005027831A3 (en) Modulators of p-selectin glycoprotein ligand 1
DK0710124T3 (da) Fremgangsmåde til sterilisering af produkter
DE602004030341D1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
AU3208397A (en) Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same
ES2187499T3 (es) Metodos y aplicaciones para elementos supresores geneticos eficientes.
IL238490A0 (en) Preparations and methods for regulating NK cell activity
DE60231665D1 (de) Agarwood aus kulturmässigem Anbau
ES2181035T3 (es) Uso de un fermentador.
PL339744A1 (en) Azabenzimidazole based compounds useful in modulating action of serinic/treoninoic proteinic kinase
JOP20220204B1 (ar) الأجسام المضادة لـ cd19 البشرية
DK1814878T3 (da) Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
BR0316880A (pt) Anticorpos contra pd-1 e usos dos mesmos
ATE493186T1 (de) Zelltrennungszusammensetzungen und -verfahren
AU2003223990A1 (en) Filtration devices
DE60331583D1 (de) Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen
BR0214250A (pt) peptìdeos que promovem a aderência, crescimento e secreção da célula
EP1501465A4 (en) Vectors with Two Isoforms of Beta-Hexafaminamide
SG146670A1 (en) Modulators of p-selectin glycoprotein ligand 1
CY1107603T1 (el) Χρηση της ανθρωπινης ορμονης αναπτυξης για την αυξηση του αριθμου των κυκλοφορουντων κυτταρων cd34+, με στοχο την ανασυνθεση των αιματοποιητικων και ανοσοποιητικων συστηματων ακολουθωντας μυελοβλαστικες ή αντιβλαστικες θepαπειες, μεσω μεταμοσχευσης, επαναμεταγγισης ή εμφυτευσης
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
MX9204714A (es) Depurador de fluidos mejorado y metodo para convertir el mismo entre los modos motorizado y manual.
ATE469552T1 (de) VERWENDUNG VON CNI-OD-FORMULIERUNGEN ZUR BEKÄMPFUNG DER WEIßEN FLIEGE
TW200507751A (en) Nematicidal compositions and methods
ATE278461T1 (de) Mikropartikel hergestellt aus cycloolefincopolymeren und deren verwendung zur kontrollierten wirkstofffreigabe